An Extension Trial Comparing Safety and Efficacy of NN5401 Plus Meal-time Insulin Aspart for the Remaining Meals With Insulin Detemir Plus Meal-time Insulin Aspart in Type 1 Diabetes (BOOST: T1)

Trial Profile

An Extension Trial Comparing Safety and Efficacy of NN5401 Plus Meal-time Insulin Aspart for the Remaining Meals With Insulin Detemir Plus Meal-time Insulin Aspart in Type 1 Diabetes (BOOST: T1)

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2016

At a glance

  • Drugs Insulin degludec/insulin aspart (Primary) ; Insulin aspart; Insulin detemir
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms BOOST-T1
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Jan 2016 Primary endpoint has been met (Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes), according to results published.
    • 16 Jan 2016 Results published in the Diabetic Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top